July 20, 2026
2 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
Zasocitinib outperforms apremilast for high-impact psoriasis sites
Zasocitinib demonstrated high rates of psoriasis clearance for hard-to-treat areas and high-impact sites, Takeda announced in a press release. Approximately 75% of participants with scalp psoriasis and 70% of those with palmoplantar psoriasis who received zasocitinib — a selective oral tyrosine kinase 2 (TYK2) inhibitor that blocks interleukin-23 and other pathways driving psoriasis
782 words~4 min read
